We reviewed the scientific evidence and clinical impact of osimertinib as adjuvant treatment in completely resected EGFR-mutant NSCLC, as maintenance treatment after chemoradiotherapy in locally advanced disease, and as a preoperative treatment in the neoadjuvant setting. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.